Close
RNS Number : 3108P
Alliance Pharma PLC
09 October 2019
 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Director's Dealing

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that it has received notice that on 7 October 2019, Peter Butterfield, Chief Executive Officer of Alliance, exercised unapproved share options over 3,137,546 ordinary shares of 1p each in the Company ("Ordinary Shares") under the Company's Share Option Plans. The average exercise price was 34.5 pence.

 

Following the exercise, on 7 October 2019, Mr Butterfield sold 2,791,546 Ordinary Shares at a price of 73.5 pence per share. Following these transactions, Mr Butterfield's total beneficial interest in the Group is 374,376 Ordinary Shares, representing approximately 0.07 per cent. of the Group's issued share capital.

 

The 3,137,546 Ordinary Shares will be admitted to trading pursuant to an existing block listing, and will rank pari passu with the existing Ordinary Shares in issue.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Peter Butterfield

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ALLIANCE PHARMA PLC

b)

Legal Entity Identifier

213800RYIWZA4Q5WPZ13

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

GB0031030819

b)

Nature of the transaction

a)   Exercise of options

b)   Sale of Ordinary Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

a)   34.5 pence

b)   73.5 pence

 

a) 3,137,546

b) 2,791,546

 

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

a) 3,137,546 Ordinary Shares, weighted average exercise price of 34.5 pence per Ordinary Share.

b) 2,791,546 Ordinary Shares, sold at a price of 73.5 pence per Ordinary Share, totalling £2,051,786.31.

 

f)

Date of the transaction

7 October 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

 

For further information:

 

Alliance Pharma plc                                                           + 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk

 

Buchanan                                                                           + 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

Numis Securities Limited                                                 + 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield

Corporate Broking: James Black

 

Investec Bank plc

+ 44 (0)  20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

 

Corporate Broking: Patrick Robb / Tejas Padalkar

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHMMMGGGLGGLZM